Antivascular therapy of cancer: DMXAA.

  title={Antivascular therapy of cancer: DMXAA.},
  author={B. C. Baguley},
  journal={The Lancet. Oncology},
  volume={4 3},
The vascular endothelium of tumour tissue, which differs in several ways from that of normal tissues, is a potential target for selective anticancer therapy. By contrast with antiangiogenic agents, antivascular agents target the endothelial cells of existing tumour blood vessels, causing distortion or damage and consequently decreasing tumour blood flow. DMXAA (5,6-dimethylxanthenone-4-acetic acid), a low-molecular-weight drug, has a striking antivascular and in some cases curative effect in… CONTINUE READING